Cohance Lifesciences Limited — PPTs, 05-08-2026: Investor Presentation

#CohanceLifesciences Q1 Update: Revenue Dip, H2 Recovery Expected!

**Business Performance:** Cohance Lifesciences saw Q1 revenue drop 23.1% YoY to INR 422.3 Cr, with Adjusted EBITDA at INR 9.2 Cr (2.2% margin). This dip was mainly due to Pharma CDMO shipment delays, softer Agrochemicals, and a significant INR 32.8 Cr loss from its NJ Bio subsidiary. Despite this, the standalone business remains robust, and the company maintains a healthy net cash position of INR 251.2 Cr. Adjusted PAT for the quarter was a loss of INR (43) Cr.

**Growth Drivers/Strategy:** The company is sharpening its focus on building an integrated nucleic-acid business, including plans to increase its stake in Sapala Organics for unified operations. It's also repositioning its Agrochemicals segment towards innovative products.

**Recent Developments:** Cohance has completed a new amidites facility at Nacharam and is progressing with product qualification. Pharma CDMO is seeing scheduled deliveries and a restocking order, with 10 molecules in Phase III development. Formulations operations have restarted, and US supplies are back on track.

**Outlook:** Management expects a rebound, forecasting sequential improvement from Q2 and stronger growth in H2 FY27. Key drivers include Pharma CDMO recovery, strong Sapala orders, and normalisation in API+ and Formulations. They also plan for H2 EBITDA growth driven by better volumes and product mix.